A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Merck Sharp & Dohme LLC130 enrolled

Overview

The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

130

Conditions

Healthy Pneumococcal Infections

Interventions

V110, pneumococcal vaccine polyvalentBIOLOGICAL

Eligibility

Sex: ALLMin age: 20 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females in good health, ages 20-40, with no history of pneumococcal vaccination Exclusion Criteria: * Subjects with a recent febrile illness * Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chemotherapy, including long-term corticosteroid therapy

Outcomes

Primary Outcomes

Immunogenicity

Secondary Outcomes

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.